Literature DB >> 1942083

Cardiac adenosine production is linked to myocardial pO2.

A Deussen1, J Schrader.   

Abstract

Experiments were performed on isolated perfused guinea-pig hearts (n = 45) to further evaluate the stimulus that triggers cardiac adenosine production. Stimulation of hearts with isoproterenol (4 nM, 20 min) enhanced left ventricular dP/dtmax, heart rate and myocardial oxygen consumption within 1 min to new steady state values, whereas coronary venous adenosine concentration only transiently increased reaching its maximum between 1 and 3 min of stimulation. Rate of accumulation of S-adenosylhomocysteine (SAH), a measure of the free cytosolic adenosine concentration, was steepest immediately following onset of stimulation and then progressively declined. Similar to adenosine, changes in coronary venous pO2 were phasic and adenosine release and pO2 closely correlated. Norepinephrine (20 nM) which increased myocardial oxygen consumption to a comparable extent as isoproterenol (4 nM) further decreased coronary venous pO2 and increased coronary venous adenosine. When myocardial oxygen supply was systematically varied by changing coronary perfusion pressure from 60 to 90 and 35 cmH2O, respectively, the adenosine release during isoproterenol (2 nM) was markedly enhanced at 35 cmH2O but blunted at 90 cmH2O. Similarly SAH accumulation was greatest at 35 cmH2O and smallest at 90 cmH2O. It is concluded that changing myocardial oxygen consumption is not a sufficient cause to enhance adenosine formation. Myocardial oxygenation as reflected by changes in coronary venous pO2 closely correlates with changes in free cardiac adenosine as evidenced by two independent indices: tissues SAH and coronary venous adenosine concentration. The stimulus triggering cardiac adenosine formation is most likely the imbalance of oxygen supply and oxygen demand.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1942083     DOI: 10.1016/0022-2828(91)90173-j

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

1.  A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine.

Authors:  E Snoeck; P Jacqmin; A Van Peer; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1999-06

2.  Adenosine concentration in the porcine coronary artery wall and A2A receptor involvement in hypoxia-induced vasodilatation.

Authors:  Ole Frøbert; Gesine Haink; Ulf Simonsen; Claus H Gravholt; Max Levin; Andreas Deussen
Journal:  J Physiol       Date:  2005-11-10       Impact factor: 5.182

Review 3.  Purine metabolism in the heart. Strategies for protection against myocardial ischaemia.

Authors:  K Ver Donck
Journal:  Pharm World Sci       Date:  1994-04-15

4.  Metabolic memory: a vascular perspective.

Authors:  Thomas W Jax
Journal:  Cardiovasc Diabetol       Date:  2010-09-14       Impact factor: 9.951

5.  Ecto-5'-nucleotidase is expressed by pericytes and fibroblasts in the rat heart.

Authors:  K Mlodzik; J Loffing; M Le Hir; B Kaissling
Journal:  Histochem Cell Biol       Date:  1995-03       Impact factor: 4.304

6.  Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors.

Authors:  M Carmen Montesinos; Avani Desai; Jiang-Fan Chen; Herman Yee; Michael A Schwarzschild; J Stephen Fink; Bruce N Cronstein
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 7.  Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.

Authors:  Allan K N Alencar; Guilherme C Montes; Eliezer J Barreiro; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  Front Pharmacol       Date:  2017-12-04       Impact factor: 5.810

Review 8.  Ectonucleotidases as bridge between the ATP and adenosine world: reflections on Geoffrey Burnstock.

Authors:  Jürgen Schrader
Journal:  Purinergic Signal       Date:  2022-05-06       Impact factor: 3.950

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.